MAY - 2023LIFE SCIENCES REVIEW7Neurodegenerative diseases like Alzheimer's disease, Friedreich ataxia, Amyotrophic lateral sclerosis, and Parkinson's disease are at an all-time high, and so is the awareness about these diseases. This has propelled the market for neurodegenerative diseases and has given rise to a strong pipeline of treatments for such conditions.According to research, the global neurodegenerative diseases market was valued at USD 40,125 million at the end of the last decade and is estimated to reach USD 53,275 million by 2030 at an astounding cumulative annual growth rate (CAGR) of 3.20 per cent. Out of this, the APAC market itself is predicted to be worth USD 13,530 million by 2030 recording a massive 5.03 per cent CAGR. This Life Sciences Review issue highlights some of the most significant developments in the APAC market for neurodegenerative diseases and the considerable expansion of the sector in recent years. It features TauRx, founded to address one of the world's most pressing unmet medical needs - Alzheimer's disease and other neurodegenerative disorders - by targeting misfolding and aggregation of tau proteins. Its mission is to discover, develop, and commercialize novel products to diagnose, treat, and cure neurodegenerative diseases caused by protein aggregation.The magazine also includes the insightful viewpoints of Steven Henck, PhD, Vice President of R&D, Integrated DNA Technologies, and Claus Feussner, Senior Vice President of Vetter Development Service, Vetter Pharma. They each address several valuable points related to treating Neurodegenerative diseases in the current technology-driven world.Write to us about how the advancements in the APAC region's neurodegenerative diseases market have affected your organisation's functioning!EDITORIALNavigating the Complexities of Neurodegenerative DiseasesCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com MAY - 2023, Vol 03, Issue - 35 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersAlex FloresDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsXavier YoungClara Matthew
< Page 6 | Page 8 >